All In Biotech

Investigational drug · Phase 3

Supportive care measures

Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

6

5 still active

All registered trials

77

Any phase or sponsor naming "Supportive care measures"

First trial start

2023

May 16, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Supportive care measures", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Esophageal Squamous Cell Carcinoma
  • Metastatic Urothelial Carcinoma
  • Locally Advanced Urothelial Carcinoma
  • Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Biliary Tract Cancer
  • Gastroesophageal Cancer
  • Non-small Cell Lung Cancer (NSCLC)
  • Non-Muscle Invasive Bladder Cancer

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Pancreatic cancer · Bladder and urothelial cancer · Stomach and esophageal cancer · Oncology · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "Supportive care measures" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 342 on PubMed

Also in development for Esophageal Squamous Cell Carcinoma

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • I-DXdDS-7300a, MK-2400Phase 317 trials

    Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • TiragolumabMTIG7192A, RO7092284Phase 311 trials

    Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer

  • Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials

    Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

  • H2 receptor antagonistPhase 34 trials

    Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer

  • KC1036Phase 33 trials

    Beijing Konruns Pharmaceutical Co., Ltd. · Ewing Sarcoma, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma (ESCC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.